Email this article Invasive aspergillosis in children in debut of acute myeloid leukemia
- Authors: Dinikina Y.V.1,2, Shadrivova O.V.3, Belogurova M.B.1,2, Dokhina N.N.1, Khostelidi S.N.3, Ignatyeva S.M.3, Bogomolova T.S.3, Klimko N.N.3
-
Affiliations:
- Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation
- St. Petersburg State Pediatric Medical University, Ministry of Health of Russia
- North-Western State Medical University named after I.I. Mechnikov
- Issue: Vol 18, No 3 (2019)
- Pages: 88-95
- Section: CLINICAL OBSERVATIONS
- Submitted: 13.09.2019
- Accepted: 13.09.2019
- Published: 13.09.2019
- URL: https://hemoncim.com/jour/article/view/265
- DOI: https://doi.org/10.24287/1726-1708-2019-18-3-88-95
- ID: 265
Cite item
Full Text
Abstract
Invasive aspergillosis (IA) is a life-threatening complication in pediatric patients with hematological malignancies. The highest incidence rates of IA were found in pediatric patients with acute myeloid leukemia (AML). We presented a case of successful treatment of IA in a patient with debut of AML with Down syndrome, analysis of IA cases in children with AML according data of the register and a literature review. 46 pediatric patients with IA were included, among them 16 (34.7%) with AML. In 3 (18.75%) pts AML was diagnosed in presentation of AML. Risk factors of IA were prolonged neutropenia (100%) and lymphocytopenia (81%). The most common clinical signs were: fever > 38.5 ºС (93.7%), cough (75%) and respiratory failure (43.7%). The lung involvement was diagnosed in 93.7% of pts, more than 2 sites of IA – in 12.5%, endophthalmitis – in 6.25%. Typical imaging finding was «halo sign» – 37.5%. According received results «probable IA» was diagnosed in 87.5% of pts and «proven» in 12.5%. Antifungal treatment received 100% of patients, with voriconazole only – 50%, combined antifungal therapy – 33.3%. Overall 12-week survival was 87.5%. Parents patients agreed to use personal data in research and publications.
About the authors
Y. V. Dinikina
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation;St. Petersburg State Pediatric Medical University, Ministry of Health of Russia
Author for correspondence.
Email: dinikina_yuv@almazovcentre.ru
ORCID iD: 0000-0002-2003-0982
Yulia V. Dinikina, MD, PhD, Head of the Department of pediiatric oncohematology and SCT Almazov National Medical Research Centre, St. Petersburg
197341, St. Petersburg, Аkkuratova st., 2
Russian FederationO. V. Shadrivova
North-Western State Medical University named after I.I. MechnikovSaint-Petersburg Russian Federation
M. B. Belogurova
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian Federation;St. Petersburg State Pediatric Medical University, Ministry of Health of Russia
ORCID iD: 0000-0002-7471-7181
Saint-Petersburg Russian Federation
N. N. Dokhina
Almazov National Medical Research Centre of the Ministry of Healthcare of the Russian FederationSaint-Petersburg Russian Federation
S. N. Khostelidi
North-Western State Medical University named after I.I. MechnikovSaint-Petersburg Russian Federation
S. M. Ignatyeva
North-Western State Medical University named after I.I. Mechnikov
ORCID iD: 0000-0002-0306-3694
Saint-Petersburg Russian Federation
T. S. Bogomolova
North-Western State Medical University named after I.I. Mechnikov
ORCID iD: 0000-0002-2450-687X
Saint-Petersburg Russian Federation
N. N. Klimko
North-Western State Medical University named after I.I. Mechnikov
ORCID iD: 0000-0001-6095-7531
Saint-Petersburg Russian Federation
References
Supplementary files
